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VimentinHistone deacetylase inhibitors (HDACIs) are now emerging as a new class of anticancer drugs. Some of them
have been used in clinical treatment for tumors, most impressively in the hematological tumors. But their
single-agent activities in epithelial-derived tumors are limited. The mechanisms of these actions of HDACIs
are not yet well understood. In this study, it was found for the ﬁrst time that HDACIs were able to induce ep-
ithelial–mesenchymal transitions (EMT) which is believed to trigger tumor cell invasion and metastasis. We
show that HDACIs induce ﬁbroblast-like morphology, up-regulate Snail and Vimentin and down-regulate
E-cadherin in epithelial cell-derived tumor cell lines. It demonstrates that HDACI treatment enhances further
Snail acetylation and reduces its ubiquitylation, and induces Snail transcription as well as Snail nuclear trans-
location in CNE2 cells. Snail knockdown by siRNAs prevents the change in cell morphology and Vimentin
up-regulation in response to HDACIs. The results suggested that Snail plays an important role in the
HDACI-induced EMT. It is very crucial for a better understanding of clinical therapeutical failure of HDACIs
in the patients with epithelial cell-derived cancers. Therefore, our results indicate that more attention should
be paid to the cancer treatment using HDACIs due to the fact that it will enhance the spread risks of cancer
cells to facilitate cancer progression and it is very important to select appropriate drugs for different tumors.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
It iswell recognized that post-transcriptionalmodiﬁcation of histones
and non-histone proteins by acetylation, phosphorylation, methylation
and ubiquitination, particularly for acetylation, plays important roles in
the control of cellular functions [1]. Histone deacetylase inhibitors
(HDACIs) can promote hyperacetylation of targeted proteins, they are
now emerging as a new class of anticancer agents with potent activity
in inhibiting proliferation and inducing differentiation of numerous he-
matologic and solid tumors including neuroblastoma, erythroleukemia,
acute myelogenous leukemia, and carcinomas of the skin, breast, pros-
tate, bladder, lung, colon, and cervix [2–7].
HDACIs can be divided into several structural classes including
hydroxamates, cyclic peptides, short chain fatty acid and benzamidesl and Biochemical Pharmacy,
ersity, No. 132 Waihuandong
uangzhou 510006, PR China.
un2345@yahoo.cn,
rights reserved.[8]. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a hydroxamic
acid derivative which was recently approved by the US Food and Drug
Administration (USFDA) for treatment of cutaneous T-cell lymphoma
(CTCL) [9]. Furthermore, Phase I clinical trials of SAHA were being
performed for the treatment of a variety of solid and hematological tu-
mors such as head and neck cancer, Hodgkin lymphoma (HL), and dif-
fuse large B-cell lymphoma (DLBCL) [10,11]. Sodium butyrate (NaB),
another potent HDACI, is produced in the colon of mammals as a result
of anaerobic bacteria fermentation of dietary ﬁber, undigested starch
andproteins [12]. It has previously been shown to induce cell cycle ar-
rest or to promote cell differentiation, and ﬁnally to induce apoptosis
in a variety of cancer cells including nasopharyngeal carcinoma, co-
lorectal cancer and cervical cancer cells, while having little effect
on normal cells [13–15]. Despite the rapid clinical progress achieved,
the mechanisms of action of HDACIs are not yet well understood. In
the present study, it was reported for the ﬁrst time that HDACIs
could induce epithelial–mesenchymal transitions (EMT) in tumor
cells. It provides a better understanding for the molecular mecha-
nisms of HDACIs' clinical effects.
EMT refers to the epithelial cells' transfer to the mesenchymal
cells in the particular physiological and pathological conditions. It
was ﬁrst recognized as a central differentiation process in early
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an important contributor to the invasion and metastasis of epithelial-
derived cancers [17,18]. The down-regulation of E-cadherin and
up-regulation of Vimentin have been regarded as the markers of EMT
[19–22]. Numerous inducers of EMT in cancer cell lines have been iden-
tiﬁed including TGF-β [23], Wnt [24], Snail/Slug [25], Twist [26], and
Six1 [27]. Because local invasion is thought to be a necessary ﬁrst step
in metastatic dissemination, EMT is hypothesized to contribute to
tumor progression. The indeed clinical evidences suggest that regula-
tors of EMT in cancer cells correlate with poor patient outcomes and
tumor aggressiveness [28,29].
As a new group of anticancer drugs, HDACIs have shown signiﬁ-
cant efﬁcacy in hematological malignancies while limited effects in
epithelial cell-derived cancers. The detailed mechanism of this phe-
nomenon remains to be elucidated. In this study, it was found that
HDACIs could induce EMT in tumor cells, then, we examined the mo-
lecular mechanisms of EMT induced by HDACIs to elucidate the rea-
sons why HDACIs are unsatisfactory in clinical epithelial cell-derived
cancer research. It will also provide a theoretical basis for a reason-
able guide of HDACIs in anti-tumor clinical research.
2. Materials and methods
2.1. Chemicals and reagents
NaB and SAHA were purchased from Sigma-Aldrich (Deisenhofen,
Germany). Bortezomib was purchased from LC Laboratories (MA,
USA). Vectors (pGL3-Basic and pRL-TK) and dual-luciferase assay kit
are products of Promega (Madison, WI, USA), the plasmid pBV-Luc/
Del-6 containing c-myc promoter (−109/+334) was purchased from
Addgene company. The monoclonal anti-ubiquitin, anti-Snail, anti-
Vimentin antibody, the polyclonal anti-β-actin and the secondary
anti-mouse antibody conjugated to HRP are products of Cell Signaling
Technology (MA, USA). Protein A/G Sepharose was purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). SYBR Premix Ex
Taq II is a product of TaKaRa BIO Inc. (TBI, Japan). The secondary
anti-mouse antibody conjugated to FITC, DAPI dye, double-stranded
siRNA Snail and Lipofectamine 2000 were purchased from Invitrogen
(Carlsbad, CA, USA). Millicell chamber (8 μm) was purchased from
Millipore (BD Biosciences, USA).
2.2. Cell culture
The human nasopharyngeal carcinoma cell line CNE2 was
established at Hunan Medical College, China [30]. HepG2 and LoVo Cell
lines were purchased from ATCC. Cells were maintained in RPMI 1640
supplemented with 10% heat-inactivated endotoxin-free Newborn Calf
Serum, 100 μg/ml streptomycin and 100 units/ml penicillin under a hu-
midiﬁed 5% CO2 atmosphere at 37 °C in an incubator.
2.3. Western blotting analysis
Western blotting assay was performed as previously described [12].
Brieﬂy, cells were lysed in cell lysis buffer containing 1% NP-40, 20 mM
Tris–HCl (pH 7.6), 0.15 M NaCl, 3 mM EDTA, 3 mM EGTA, 1 mM
phenylmethylsulfonyl ﬂuoride, 20 mg/ml aprotinin, and 5 mg/ml
leupeptin. Lysates were cleared by centrifugation and denatured by
boiling in Laemmli buffer. Equal amounts of protein samples were sep-
arated on 12% sodium dodecyl sulfate (SDS)–polyacrylamide gels and
electrophoretically transferred to nitrocellulose membranes. Following
blockingwith 5% non-fatmilk at room temperature for 2 h,membranes
were incubated with the primary antibody at 1:1000 dilution overnight
at 4 °C and then incubated with a horseradish peroxidase-conjugated
secondary antibody at 1:5000 dilution for 1 h at room temperature.
Speciﬁc immune complexes were detected using western blotting
Plus Chemiluminescence Reagent (Life Science, Inc., Boston, MA).2.4. Wound healing
CNE2 cells (4×105) were cultured on 6-well plates. After 24 h of
cultivation, cells covered the whole bottom of the well. A deﬁned
scratch was applied on the well bottom, which detached cells within
a deﬁnite corridor. Cells treated with or without NaB or SAHA for
24 h. Over a time period of 24 h, the percentage recovering of the
scratch wound was monitored.
2.5. Cell invasion assay
The cell invasion assay was performed as follows: ﬁrst, 6.5-mm-
diameter polycarbonate ﬁlters (8 μm pore size) were coated with
Matrigel TM, dried, and reconstituted at 37 °C with appropriate RPMI
1640 before use. Then 1×105 CNE2 cells per chamber were added to
the upper chamber in RPMI 1640 containing 1% FCS, while to the lower
chamber in RPMI 1640 containing 10% FCS. Cells treatedwith or without
NaB or SAHA for 24 h, the drug concentrationwas the same in the lower
and upper chambers. After 24 h incubation at 37 °C in a CO2 incubator,
the number of cells that had spread through the pores of the ﬁlter and
into the lower chamber was counted under a phase contrast microscope
(ﬁve ﬁelds per chamber). Each invasion experiment was carried out in
duplicate and repeated in three independent experiments.
2.6. Immunoprecipitation
To assess the ubiquitination of Snail, after treatment with NaB or
SAHA for 4 h, cells were washed twice with ice-cold PBS and harvested
at 4 °C in immunoprecipitation lysis buffer (50 mM HEPES, pH 7.5,
150 mM NaCl, 2 mM EDTA, 0.5% NP-40, 10% glycerol, 1 mM NaF, 1 mM
Na3VO4, 1 mM dithiothreitol, 1 mM 4-(2-aminoethyl) benzenesulfonyl
ﬂuoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin and 1 μg/ml pepstatin).
Equal amounts of protein were immunoprecipitated using anti-Snail an-
tibody or negative control IgG, and the immune complexes were bound
to protein A/G Sepharose. The beads were washed with lysis buffer and
subjected to western blotting with anti-ubiquitin or anti-acetylate
antibody.
2.7. Quantitative Real-Time PCR
To achieve better quantiﬁcation of Snail mRNA expression, levels
of Snail mRNA were measured by Quantitative Real-Time PCR. CNE2
(2×105) cells were plated on 6-well plates. After treatment with
NaB or SAHA for 24 h, CNE2 cells were washed twice with ice-cold
PBS. Total mRNA was extracted with TRIZOL reagent. The ﬁrst strand
of cDNA was generated from 2 μg total RNA using oligo-dT primer
and Superscript II Reverse Transcriptase (GIBCO BRL, Grand Island,
NY, USA). Quantitative Real-Time PCR was run on an iCycler (Bio-rad,
Hercules, USA) using validated primers for β-actin, Snail and SYBR
Premix Ex Taq II (Takara, Japan) for detection. The cycle number
when the ﬂuorescence ﬁrst reaches a preset threshold (Ct), allow
the quantiﬁcation of the speciﬁc template concentration. Transcripts
of the housekeeping gene β-actin in the same incubations were
used for internal normalization. The primer pairs used in the subse-
quent Quantitative Real-Time PCR reactions were as follows: Snail,
forward 5′-GACCACTATGCCGCGCTCTT-3′ and reverse 5′-TCGCTGTA
GTTAGGCTTCCGATT-3′; β-actin, forward 5′-TGGCACCC AGCACAAT
GAA-3′ and reverse 5′-CTAAGTCATAGTCCGCCTAGAAGCA-3′.
2.8. Transient transfection and reporter genes assay
Itwas demonstrated that the sequence−78/+59was denominated
as the minimal Snail promoter [31]. To examine the effect of NaB and
SAHA on transcriptional activity of Snail, we used the sequence −
797/+59 of promoter sequence of Snail cloned upstream of the lucifer-
ase reporter gene of pGL3-Basic to get the recombinant plasmids of
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moter using PCR technology. The primer pairs used in the PCR reactions
were as follows: forward 5′-CGGGGTACCCAAAGCACACTTCCCTTTGC-3′,
reverse 5′-GGAAGA TCTTGGTCGAGGCACTGGGGTC-3′. For measuring
the transcriptional activity of Snail, cells were transfected with 0.2 μg
DNA/cm2 per plasmid and lipofectamine 2000 reagent (Invitrogen,
USA) according to the manufacturer's instructions. Transfection
efﬁciency was normalized by cotransfection with pRL-TK. Transcrip-
tional activity was determined by a luminometer, using a dual-
luciferase assay kit. Resultswere displayed as the ratios between the ac-
tivity of the reporter plasmid and pRL-TK.
2.9. Confocal microscopy for Snail
Cells were grown on chamber slides. After 12 h of cultivation, cells
were stimulated with NaB or SAHA for 4 h. Cells were ﬁxed in 4%
paraformaldehyde for 30 min and blocked with goat serum for
30 min at 37 °C, then incubated with anti-Snail antibody at 1:100
for 1 h at 37 °C. Slides were washed with PBS and incubated with a
secondary anti-mouse antibody conjugated to FITC at 1:1000 for
45 min at 37 °C. After washed by PBS, the cells were incubated with
DAPI (10 μg/ml) for 10 min to visualize cell nuclei. Samples were ex-
amined with Confocal Laser Scanning Microscopy (Zeiss, Germany) to
analyze nuclear translocation of Snail.
2.10. In vitro gene silencing
The Validated Stealth TM Negative Control and double-stranded
Snail-speciﬁc small interference RNA (siRNA) oligonucleotides wereFig. 1. HDACI-induced EMT inepithelial cell-derived tumor cells. (A) Cellswere treatedwith orw
LoVo and HepG2 cell lines were detected by a phase contrast microscope. (B–D) CNE2 (B), LoVo
then detected theprotein expression of Vimentin andE-cadherin bywesternblotting.β-actin serpurchased from Invitrogen with the following sequences: sense:
5′-ACUCAGAUGUCAAGAAGUAdTdT-3′ and antisense: 5′-UACUUCUU
GACAUCUGAGUTdTd-3′ (Snail①). sense: 5′-CCUUCG UCCUUCUCCU
CUAdTdT-3′ and antisense: 5′-UAGAGGAGAAGGACGAAGGTd Td-3′
(Snail②). CNE2 cells were transfected using Lipofectamine 2000
reagent according to the manufacturer's instructions and incubated
for 48 h before harvest.
2.11. Statistical analyses
All values were reported as mean±SEM of three independent ex-
periments unless otherwise speciﬁed. Data were analyzed by
two-tailed unpaired Student's t-test between two groups and by
One-Way ANOVA followed by Bonferroni test for multiple compari-
son involved. These analyses were performed using GraphPad Prism
Software Version 5.0 (GraphPad Software Inc., La Jolla, CA). pb0.05
was considered statistically signiﬁcant.
3. Results
3.1. HDACIs induced EMT in epithelial cell-derived tumor cells
A variety of tumor cell lines originated from epithelial cells such as
CNE2, LoVo and HepG2 were treated with or without 3 mM NaB or
3 μM SAHA for 24 h, and then the phenotypic changes were recorded
under a phase contrast microscope. After treatment with NaB or SAHA,
cell lines including CNE2, LoVo and HepG2 became scattered and
adopted a typical ﬁbroblast-like morphology of mesenchymal cells
(Fig. 1A). It suggested that HDACIs could induce phenotypic change ofithout 3 mMNaBor 3 μMSAHA for 24 h, and then thephenotypic changes of EMT inCNE2,
(C) and HepG2 (D) Cells were treated with or without 3 mMNaB or 3 μM SAHA for 24 h,
ved as the loading control. Similar resultswere obtained in three independent experiments.
Fig. 2. HDACIs induced the invasion and metastasis of tumor cells. CNE2 cells were
treated with or without 3 mM NaB or 3 μM SAHA for 24 h, and then the invasion
and metastasis of CNE2 cells were detected by wound healing technology and cell in-
vasion assay, *pb0.01. (A) In the processes of wound healing technology, the scratch
wound was monitored under a phase contrast microscope after treatment with
3 mM NaB or 3 μM SAHA for 0 h, 12 h and 24 h, respectively. (B) In the processes of
cell invasion assay, after treatment with 3 mM NaB or 3 μM SAHA for 24 h, cells that
had spread through the pores of the ﬁlter and into the lower chamber were stained
with hematoxylin and counted under a phase contrast microscope (ﬁve ﬁelds per
chamber).
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up-regulation of Vimentin and down-regulation of E-cadherin are im-
portant molecular markers of EMT. Therefore, cells were treated with
or without 3 mM NaB or 3 μM SAHA for 24 h, and then the expression
of Vimentin and E-cadherin was detected by western blotting. As
shown in Fig. 1B–D, signiﬁcant up-regulation of Vimentin protein and
down-regulation of E-cadherin protein were observed in CNE2, LoVo
and HepG2 cell lines after stimulation with NaB or SAHA. All these re-
sults suggested that NaB and SAHA could induce the EMT in tumor
cells that originated from the epithelial cells.
3.2. HDACIs induced invasion and metastasis of tumor cells
EMT is an important mechanism taking place during tumor inva-
sion to generate singly invading cells. To detect the changes in inva-
sion and metastasis ability of tumor cells after EMT, the CNE2 cell
line in which phenotypic change of EMT induced by HDACIs is partic-
ularly signiﬁcant was chosen for further research. Cells were treated
with or without 3 mM NaB or 3 μM SAHA for 24 h, then detected
the invasion and metastasis by wound healing technology and cell in-
vasion assay respectively. The results of wound healing showed that
the scratch wound of cells treated with 3 mM NaB or 3 μM SAHA be-
comes narrower, particularly for cells treated with drugs for 12 h, the
scratch disappeared, and the percentage recovery of the scratch
wound was about 70%, while in control group, the scratch wound
remained obvious, and the percentage recovery of the scratch wound
was about 10% (Fig. 2A). Furthermore, the results of cell invasion
assay revealed that after treatment with 3 mM NaB or 3 μM SAHA
for 24 h, the number of cells that had spread through the pores of
the ﬁlter and into the lower chamber increased signiﬁcantly as
compared with the control (Fig. 2B). Collectively, these ﬁndings
suggested that HDACIs could trigger the invasion and metastasis
of CNE2 cells after EMT.
3.3. HDACIs induced tumor cell EMT primarily via up-regulation of Snail
It is commonly known that the zinc ﬁnger transcription factor
Snail is activated by most pathways triggering EMT and acts as a mo-
lecular organizer by down-regulating the epithelial genes and
up-regulating the mesenchymal genes. Therefore, to investigate the
molecular mechanisms of HDACIs on induction of tumor EMT, cells
were treated with or without 3 mM NaB or 3 μM SAHA for 4–48 h,
and then the Vimentin and Snail protein were detected by western
blotting. As shown in Fig. 3, in the three cell lines CNE2, LoVo and
HepG2, the expression of Vimentin and Snail was signiﬁcantly elevat-
ed by HDACIs via a time-dependent manner. The up-regulation of
Vimentin protein was detected obviously starting from 24 h after
treatment with HDACIs, while the expression of Snail protein signiﬁ-
cantly increased after cells were treated with HDACIs for 4 h and was
enhanced by continuous exposure to HDACIs, which is earlier than
the up-regulation of Vimentin protein. These results suggested that
during the process of EMT induced by HDACIs, the up-regulation of
Snail may act as an incentive to the up-regulation of Vimentin
which is an important molecular marker of EMT.
3.4. HDACIs up-regulated Snail partially via inhibition Snail degradation
The above results revealed that the expression of Snail protein in-
creased signiﬁcantly after treatment with HDACIs for 4 h. Therefore, to
further investigate the shorter time for up-regulation of Snail protein
by HDACIs, CNE2 cells were treated with or without 3 mM NaB or
3 μM SAHA for 0.5c4 h, then Snail and β-catenin protein were detected
by western blotting. The expression of Snail protein increased signiﬁ-
cantly after exposure to HDACIs for 1 h, while the expression of
β-catenin protein was not inﬂuenced by HDACIs (Fig. 4A,B). The fact
that HDACIs elevated the expression of Snail protein in such a shorttime revealed that the up-regulation of Snail quantity partially may be
via post-transcriptional processes. Snail is activated by most pathways
triggering EMT via down-regulating epithelial genes and up-regulating
mesenchymal genes. As β-catenin, Snail is also negatively regulated by
glycogen synthase kinase-3β (GSK-3β) which is maintained in an active
state (dephosphorylation) in resting epithelial cells, then it promotes
Snail's nuclear export and cytoplasmic degradation [32]. Therefore, if
GSK-3β is phosphorylated, it will be maintained in an inactive state
Fig. 3. HDACIs induced tumor EMT primarily by up-regulating of Snail expression. CNE2 (A), LoVo (B) and HepG2 (C) Cell lines were treated with or without 3 mM NaB or 3 μM
SAHA for 4–48 h. Vimentin and Snail protein were detected by western blotting. β-actin served as the loading control. Similar results were obtained in three independent
experiments.
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Snail, resulting in up-regulation of Snail and β-catenin. To determine
whether GSK-3β is involved in the HDACI-induced up-regulation of
Snail protein, cells were treated with or without 3 mM NaB or 3 μM
SAHA for 5 min–1 h, and then the phosphorylation of GSK-3β and
total GSK-3β were detected by western blotting. The results showed
that HDACIs cannot enhance the phosphorylation of GSK-3β (Fig. 4C).
The results suggested that phosphorylation of GSK-3β is not themecha-
nism for HDACI-induced up-regulation of Snail. It also provided the ex-
planation that the expression of β-catenin protein was not inﬂuenced
by HDACIs. To further investigate the molecular mechanisms of HDACIs
up-regulating Snail at post-transcriptional level, cells were treated with
or without 3 mM NaB or 3 μM SAHA, at the meantime, every group in-
cluding the control was treated with 2 μM Bortezomib to inhibit degra-
dation of ubiquitinated proteins. After cells were treated with drugs for
4 h, total proteins in the cell lysate were subjected to immunoprecipita-
tion with an anti-Snail antibody or negative control IgG. The acetylation
and ubiquitination of Snail levels in immune complex were detected by
western blotting with an anti-acetyalte and an anti-ubiquitin antibody.
The results demonstrated that HDACIs could up-regulate acetylation of
Snail and down-regulate ubiquitination of Snail (Fig. 4D,E). Therefore,
to up-regulate Snail, HDACIs may inhibit the ubiquitination of Snail via
promoting its acetylation at post-transcriptional level.3.5. HDACIs induced the transcription expression of Snail and promoted
Snail nuclear translocation
Although the up-regulation of Snail protein by HDACIs at post-
transcriptional level has been demonstrated, it still did not exclude
that HDACIs can promote the transcriptional expression of Snail pro-
tein. Therefore, whether HDACIs could promote transcriptional acti-
vation of Snail was examined by transfecting the promoter reporter
gene plasmid pGL3-Basic-Snail-luc into CNE2 cells. The transfection
efﬁciency was normalized by cotransfection with pRL-TK, and then
cells were treated with or without 3 mM NaB or 3 μM SAHA for 24 h.
HDACIs are known to rather unspeciﬁcally induce the activity of many
promoters, they can up-regulate some promoters, and also down-
regulate many promoters. It was reported that HDACIs down-regulate
c-myc in the transcriptional level [33], so we applied the plasmid
pBV-Luc/Del-6 containing c-myc promoter (−109/+334) as the con-
trol. Dual-Glo-Luciferase analysis revealed that HDACIs signiﬁcantly en-
hanced the activity of pGL3-Basic-Snail-luc (Fig. 5A), they while
signiﬁcantly decreased the activity of pBV-Luc/Del-6 (Fig. 5B). It
suggested that HDACIs could activate the promoter of Snail thereby pro-
moting the transcriptional activation of Snail. Further evidences were
provided by the results of Fig. 5C. CNE2 cells were treated with or with-
out 3 mM NaB or 3 μM SAHA for 24 h. Snail mRNA was detected by
Fig. 4. The up-regulation of Snail protein by HDACIs partially via inhibiting the degradation of Snail. (A–B) CNE2 cells were treated with or without 3 mMNaB or 3 μM SAHA for 0.5–4 h,
and then Snail and β-catenin protein were detected bywestern blotting. β-actin served as the loading control. Similar results were obtained in three independent experiments. (C) CNE2
cells were treated with or without 3 mM NaB or 3 μM SAHA for 5 min–1 h. The phosphorylation of GSK-3β and total GSK-3β were detected by western blotting. β-actin served as the
loading control. Similar results were obtained in three independent experiments. (D-E) CNE2 cells were treated with or without 3 mM NaB or 3 μM SAHA, at the mean time, every
group including control was treated with 2 μM Bortezomib. After cells were treated with drugs for 4 h, total proteins in the cell lysate were subjected to immunoprecipitation with an
anti-Snail antibody or negative control IgG. The acetylation or ubiquitination of Snail levels in immune complex was detected by western blotting with an anti-acetyalte (D) or an
anti-ubiqutin (E) antibody (upper panel). The membrane was stripped of antibodies and immunoblotted with an anti-Snail antibody (lower panel).
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exhibited a signiﬁcant elevation of transcriptional activation of Snail.
The fold increase of mRNA was more than three (Fig. 5C). These results
suggested that HDACIs also promoted transcriptional expression of
Snail protein. However, Snail activates target genes including Vimentin
must follow Snail enters into the cell nuclear. HDACIs can promote Snail
enters into cell nuclear compared to control. Therefore, the nuclear
translocation of Snail was detected by immunoﬂuorescence. CNE2
cells were grown on chamber slides, incubated with or without 3 mM
NaB or 3 μM SAHA for 2 h. Then the nuclear localization of Snail was
assessed by confocal microscopy with an anti-Snail antibody. The re-
sults revealed that therewas a signiﬁcant elevation of nuclear transloca-
tion of Snail after treatment of cells with HDACIs for 2 h (Fig. 5D).
Generally, our results indicated that HDACIs could promote transcrip-
tional activation and nuclear translocation of Snail, which was the
mechanism for explaining HDACIs on activation of target genes
Vimentin and E-cadherin and induction of EMT.
3.6. siRNA-mediated gene silencing of Snail repressed the HDACI-induced
EMT
In order to verify the hypothesis that HDACIs induced EMT via
up-regulation of Snail protein and promoted the nuclear transloca-
tion of Snail, the expression of Snail in CNE2 cells was silenced by
transfecting it with siRNAs. It demonstrated that Snail siRNA silenced
the expression of Snail signiﬁcantly, while the negative siRNA failed
to inhibit the expression of Snail (Fig. 6A). Therefore, Snail siRNA iseffective for silencing Snail expression. As demonstrated in Fig. 1, cells
treated with HDACIs had the morphological changes of EMT and signif-
icantly elevated the expression of Vimentin, however, after transfection
with Snail siRNAs for 24 h, the morphological changes of EMT for cells
treated with 3 mM NaB or 3 μM SAHA were not observed anymore,
and the expression of Vimentin decreased almost to that of the control
group. As anticipated, NaB and SAHA still induced morphological
changes of EMT and enhanced the expression of Vimentin in cells
transfected with negative siRNAs (Fig. 6B,C). Therefore, the present re-
sults demonstrated that up-regulation of Snail was crucial for HDACI-
induced EMT.4. Discussion
HDACIs are now emerging as a new class of anticancer agents with
potent activity in the inhibition of proliferation and induction of apo-
ptosis and differentiation in a wide spectrum of tumors, most impres-
sively in the hematological cancers [34]. Although HDACIs have
shown efﬁcacy in hematological malignancies, their single-agent ac-
tivity in epithelial-derived tumors such as lung cancer, renal cell can-
cer, head and neck cancer has been limited [10,35,36]. In the present
study, we demonstrated for the ﬁrst time that the mechanism respon-
sible for the limited clinical outcomes of single-agent activity of
HDACIs on epithelial-derived cancers is that HDACIs can induce
EMT through up-regulation of Snail protein and promotion of its nu-
clear translocation, which promotes invasion and metastasis of tumor
Fig. 5. HDACIs induced the transcription expression of Snail and promoted Snail nuclear translocation. (A–B) Cells were transfected with pGL3-Basic-Snail-luc reporter plasmid (A) or
plasmid pBV-Luc/Del-6 containing c-myc promoter (B) and treated with or without 3 mMNaB or 3 μM SAHA for 24 h. Luminescence was measured by a luminometer. pRL-TK plasmids
served as the correcting transfection efﬁciency. Results were expressed as the ratios between the activity of the reporter plasmid and pRL-TK. *pb0.001; (C) cells were treated with or
without 3 mM NaB or 3 μM SAHA for 24 h. Snail mRNA was detected by Quantitative Real-Time PCR. (D) Cells grown on chamber slides were treated with or without 3 mM NaB or
3 μM SAHA for 4 h. Immunoﬂuorescence and confocal microscopy were performed as described in Section 2. Scale bar, 20 μm.
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dence suggests that HDACIs combined with other anticancer agents are
actually quite effective against solid tumors because anticancer agents
involve targeting tumor cell apoptosis, inhibition of proliferation, gene/
proteinmodulation, angiogenesis andmetastasis. On account of HDACIs'
ability to alter the expression of apoptotic proteins, combination strate-
gies are being tested in an effort to increase apoptosiswithin tumor cells,
these combinational strategies resulted in synergistic cytotoxicity in nu-
merous solid and hematological cancer cell lines. Furthermore, combin-
ing HDACIs with a few strategies targeting angiogenesis is currently
under development for its promising clinical translation [37]. Therefore,
HDACIs combined with different anticancer agents may have different
effects because of their various targets, it also provide the explanation
for the effective action of HDACIs combined with other anti-tumor
agents against solid tumors.
HDACIs inhibit the growth and induce the apoptosis of tumor cells
mainly by inhibiting the activity of histone deacetylase to promote acety-
lation of the lysine residues in the N-terminal tails of nucleosomal core
histones and then activating the expression of tumor suppressor genes.
Acetylation can regulate protein stability in a sophisticated manner and
by surprisingly diverse mechanisms [38]. Acetylation of proteins can pro-
mote enhanced degradation. Previous studies indicated that acetylation
of angiogenesis regulator HIF-1α, transcription factor GATA1, pRb and
indoleamine 2, 3-dioxygenase (IDO) protein can increase proteasomal
degradation [12,39–41]. However, acetylation of lysines can equallyblock ubiquitination of the same residue, thereby preventing proteasomal
degradation [42–45]. Snail is a highly unstable protein and is regulated by
an integrated and complex signaling network at the transcriptional and
post-transcriptional levels including GSK-3β pathways [46]. In this
study, our observations suggested that HDACIs up-regulate Snail protein
at the post-transcriptional level not via promoting phosphorylation of
GSK-3β, but via promoting acetylation of Snail thereby inhibiting its
ubiquitination to repress the degradation (Fig. 4). This is most likely due
to acetylation of lysines which can block ubiquitination at the same resi-
due, thus preventing proteasomal degradation. Furthermore, we demon-
strated that HDACIs can also up-regulate Snail protein via promotion of
transcriptional expression (Fig. 5A,C). Snail is a transcriptional factor
which regulates gene expression after it enters into the cell nuclear. In
this study, we reported that HDACIs not only up-regulated Snail protein
through transcriptional and post-transcriptional levels, but also promoted
Snail nuclear translocation (Fig. 5D). It provided further clariﬁcations for
the mechanism to explain HDACI-induced EMT in tumor cells.
In order to investigate the causal relationship between the
up-regulation of Snail and EMT, cells were pre-transfected with Snail-
speciﬁc siRNA for 24 h before treating them with HDACIs. The results
revealed that HDACIs did not induce the morphological changes of
EMT and up-regulate the expression of Vimentin any more (Fig. 6). It
clearly demonstrated that up-regulation of Snail plays a crucial role on
HDACI-induced EMT. Furthermore. It was shown that Snail-speciﬁc
siRNA also rescues HDACi-induced migration/invasion (data not
Fig. 6. siRNA-mediated gene silencing of Snail repressed the HDACIs-induced EMT. (A) CNE2 cells were transfected with or without negative control siRNA or Snail siRNA for 24 h.
The interference effects of Snail protein were detected by western blotting. β-actin served as the loading control. Similar results were obtained in three independent experiments.
(B–C) CNE2 cells were transfected with or without negative control siRNA or Snail siRNA for 24 h, then cells were treated with or without 3 mM NaB or 3 μM SAHA for 24 h. Mor-
phological changes of CNE2 cells were observed under a phase contrast microscope (B), the expression of Vimentin was detected by western blotting (C). β-actin served as the
loading control. Similar results were obtained in three independent experiments.
670 G.-M. Jiang et al. / Biochimica et Biophysica Acta 1833 (2013) 663–671shown). Therefore, our results suggested that Snail can be designed
as a target for inhibition of EMT. It can reduce the spread of risk of
tumor cells induced by HDACIs in clinical cancer therapy.
Generally, these facts and speculations suggested that as a new class
of anticancer agents, HDACIs are also able to induce EMT resulting in en-
hancing the invasion and metastasis of tumor cells. Furthermore, this
study provided the mechanisms for explaining HDACI-induced EMT,
which is primarily through the promotion of transcriptional expression
and inhibition of intracellular protein degradation to up-regulation of
Snail protein and promotion of its nuclear translocation. Our results in-
dicated that more attention should be paid to the cancer treatment
using HDACIs due to the fact that it will enhance the spread of risks of
tumor cells. From another angle, the present study suggested that
HDACIs may be more applicable to the prevention and treatment for
some non-epithelial cell-derived cancers, because EMT only occurs in
epithelial cell-derived tumors. Last but not least, this study also provid-
ed an understanding of the mechanisms by which HDACIs have shown
signiﬁcant efﬁcacy in hematological malignancies while limited effects
in epithelial cell-derived cancers. Therefore, it is very important to se-
lect the appropriate drugs for different tumors.Conﬂict of interest statement
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